Interaction of ribosomal protein L22 with casein kinase 2α: A novel mechanism for understanding the biology of non-small cell lung cancer

被引:14
|
作者
Yang, Mingxia [1 ]
Sun, Haibo [2 ]
He, Ji [4 ]
Wang, Hong [3 ]
Yu, Xiaowei [1 ]
Ma, Lei [2 ]
Zhu, Changliang [2 ]
机构
[1] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Resp Med, Changzhou 213000, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Pathogen Biol, Nanjing 210029, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Resp Med, Nanjing 210029, Jiangsu, Peoples R China
[4] Xiamen Entry Exit Inspect & Quarantine Bur, State Key Lab Monitoring & Detect Med Vectors, Xiamen 361012, Fujian, Peoples R China
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; ribosomal protein L22; TAP; protein-protein interaction; casein kinase 2 alpha; phosphorylation; DOWN-REGULATION; CK2; ACTIVATION; TUMORS; GENE; RNA; RIBOSOMAL-PROTEIN-L22; IDENTIFICATION; SPECIFICITY; EXPRESSION;
D O I
10.3892/or.2014.3187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dysfunction of ribosomal proteins (RPs) may play an important role in molecular tumorigenesis, such as lung cancer, acting in extraribosomal functions. Many protein-protein interaction studies and genetic screens have confirmed the extraribosomal capacity of RPs. As reported, ribosomal protein L22 (RPL22) dysfunction could increase cancer risk. In the present study, we examined RPL22-protein complexes in lung cancer cells. Tandem affinity purification (TAP) was used to screen the RPL22-protein complexes, and GST pull-down experiments and confocal microscopy were used to assess the protein-protein interaction. The experiment of kinase assay was used to study the function of the RPL22-protein complexes. The results showed that several differentially expressed proteins were isolated and identified by LC-MS/MS, which revealed that one of the protein complexes included casein kinase 2 alpha (CK2 alpha). RPL22 and CK2 alpha interact in vitro. RPL22 also inhibited CK2 alpha substrate phosphorylation in vitro. This is the first report of the RPL22-CK2 alpha relationship in lung cancer. Dysregulated CK2 may impact cell proliferation and apoptosis, key features of cancer cell biology. Our results indicate that RPL22 may be a candidate anticancer agent due to its CK2 alpha-binding and -inhibitory functions in human lung cancer.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 50 条
  • [41] TAZ is a novel oncogene in non-small cell lung cancer
    Zhou, Z.
    Hao, Y.
    Liu, N.
    Raptis, L.
    Tsao, M-S
    Yang, X.
    ONCOGENE, 2011, 30 (18) : 2181 - 2186
  • [42] Understanding BRAF mutation in non-small cell lung cancer patients
    Tine, Mariaenrica
    Squarzoni, Giulia
    Ortolan, Davide
    Pezzuto, Federica
    Calabrese, Fiorella
    Squarzoni, Giulia
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [43] TAZ is a novel oncogene in non-small cell lung cancer
    Z Zhou
    Y Hao
    N Liu
    L Raptis
    M-S Tsao
    X Yang
    Oncogene, 2011, 30 : 2181 - 2186
  • [44] Novel approaches to the treatment of non-small cell lung cancer
    Ferreira, CG
    Huisman, C
    Giaccone, G
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2002, 41 (01) : 57 - 77
  • [45] Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines
    Loprevite, M
    Favoni, RE
    de Cupis, A
    Pirani, P
    Pietra, G
    Bruno, S
    Grossi, F
    Scolaro, T
    Ardizzoni, A
    LUNG CANCER, 2001, 33 (01) : 27 - 39
  • [46] Novel Therapeutic Targets in Non-small Cell Lung Cancer
    Janku, Filip
    Garrido-Laguna, Ignacio
    Petruzelka, Lubos B.
    Stewart, David J.
    Kurzrock, Razelle
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1601 - 1612
  • [47] Novel Targets in Advanced Non-Small Cell Lung Cancer
    Liu, Stephen, V
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07) : 426 - 429
  • [48] Novel approaches for the treatment of non-small cell lung cancer
    Bonomi, P
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 45 - 49
  • [49] A novel biologic classification of non-small cell lung cancer
    Nia, PS
    Colpaert, C
    Vermeulen, P
    Van Merck, E
    Van Schil, P
    LUNG CANCER, 2005, 49 : S143 - S144
  • [50] NOVEL TARGETS AND THERAPIES IN NON-SMALL CELL LUNG CANCER
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S93 - S93